A PHASE II MULTICENTER, DOUBLE-BLIND, RANDOMIZED, PLACEBO-CONTROLLED DOSE TITRATION STUDY TO EVALUATE THE SAFETY, TOLERABILITY AND PHARMACODYNAMIC EFFECTS OF CK-2017357 IN PATIENTS WITH AMYOTROPHIC LATERAL SCLEROSIS (ALS)
Principal Investigator(s)
Jackson,Carlayne E
Funded by
CYTOKINETICS
Research Start Date
Status
Inactive